CL2014001602A1 - Formulacion en suspension que incluye al menos un antibiotico de cefalosporina o una sal del mismo, un aceite y un disolvente de acetato de glicerol; metodo de preparacion; y su uso para tratar o prevenir una infeccion bacteriana. - Google Patents

Formulacion en suspension que incluye al menos un antibiotico de cefalosporina o una sal del mismo, un aceite y un disolvente de acetato de glicerol; metodo de preparacion; y su uso para tratar o prevenir una infeccion bacteriana.

Info

Publication number
CL2014001602A1
CL2014001602A1 CL2014001602A CL2014001602A CL2014001602A1 CL 2014001602 A1 CL2014001602 A1 CL 2014001602A1 CL 2014001602 A CL2014001602 A CL 2014001602A CL 2014001602 A CL2014001602 A CL 2014001602A CL 2014001602 A1 CL2014001602 A1 CL 2014001602A1
Authority
CL
Chile
Prior art keywords
treat
salt
oil
preparation
prevent
Prior art date
Application number
CL2014001602A
Other languages
English (en)
Inventor
Alawi Fadil Al
Karthigeyan Nanjan
Original Assignee
Bayer New Zealand Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=48668892&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CL2014001602(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Bayer New Zealand Ltd filed Critical Bayer New Zealand Ltd
Publication of CL2014001602A1 publication Critical patent/CL2014001602A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/542—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/545—Compounds containing 5-thia-1-azabicyclo [4.2.0] octane ring systems, i.e. compounds containing a ring system of the formula:, e.g. cephalosporins, cefaclor, or cephalexine
    • A61K31/546—Compounds containing 5-thia-1-azabicyclo [4.2.0] octane ring systems, i.e. compounds containing a ring system of the formula:, e.g. cephalosporins, cefaclor, or cephalexine containing further heterocyclic rings, e.g. cephalothin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/44—Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/0068—Rumen, e.g. rumen bolus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Dispersion Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Physiology (AREA)
  • Nutrition Science (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Cephalosporin Compounds (AREA)
  • Medicinal Preparation (AREA)
CL2014001602A 2011-12-23 2014-06-18 Formulacion en suspension que incluye al menos un antibiotico de cefalosporina o una sal del mismo, un aceite y un disolvente de acetato de glicerol; metodo de preparacion; y su uso para tratar o prevenir una infeccion bacteriana. CL2014001602A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
NZ59738911 2011-12-23

Publications (1)

Publication Number Publication Date
CL2014001602A1 true CL2014001602A1 (es) 2014-10-24

Family

ID=48668892

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2014001602A CL2014001602A1 (es) 2011-12-23 2014-06-18 Formulacion en suspension que incluye al menos un antibiotico de cefalosporina o una sal del mismo, un aceite y un disolvente de acetato de glicerol; metodo de preparacion; y su uso para tratar o prevenir una infeccion bacteriana.

Country Status (15)

Country Link
KR (1) KR20140102319A (es)
CN (1) CN104080456A (es)
AU (1) AU2012359296B2 (es)
BR (1) BR112014014786A2 (es)
CL (1) CL2014001602A1 (es)
CO (1) CO7101241A2 (es)
CR (1) CR20140355A (es)
DO (1) DOP2014000146A (es)
IL (1) IL233299A0 (es)
MX (1) MX2014007735A (es)
MY (1) MY167596A (es)
NI (1) NI201400064A (es)
PE (1) PE20142373A1 (es)
PH (1) PH12014501384A1 (es)
WO (1) WO2013095166A1 (es)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL2874624T3 (pl) 2012-07-17 2020-07-27 Bayer New Zealand Limited 3 Argus Place Hillcrest, Auckland 0627 / NZ Wstrzykiwalne formulacje antybiotykowe i sposoby ich zastosowania
US9452155B2 (en) 2012-07-17 2016-09-27 Bayer New Zealand Ltd Injectable antibiotic formulations and their methods of use
EP3934618B1 (en) 2019-03-06 2026-04-29 Zoetis Services LLC Ready-to-use injectable formulations

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2013755C (en) * 1989-04-05 1993-11-30 Simon Benita Medicinal emulsions
KR20040015622A (ko) * 2002-08-13 2004-02-19 대한뉴팜(주) 세프티오푸르나트륨을 활성성분으로 함유하는 현탁주사액조성물
CN1517090A (zh) * 2003-01-20 2004-08-04 王玉万 含抗菌药物的兽用混悬注射剂或乳剂
US7767860B2 (en) * 2007-09-06 2010-08-03 Auspex Pharmaceuticals, Inc Substituted amino alcohols
CN101401787B (zh) * 2008-11-19 2011-05-18 肖希龙 一种头孢噻呋长效注射液及其制备方法
CN101953889B (zh) * 2010-09-07 2013-04-10 西北农林科技大学 一种复方头孢噻呋混悬乳剂注射液及其制备方法

Also Published As

Publication number Publication date
AU2012359296B2 (en) 2014-12-11
KR20140102319A (ko) 2014-08-21
CR20140355A (es) 2014-10-29
MX2014007735A (es) 2014-08-01
MY167596A (en) 2018-09-20
PE20142373A1 (es) 2015-02-11
NI201400064A (es) 2014-11-28
DOP2014000146A (es) 2014-07-31
IL233299A0 (en) 2014-08-31
AU2012359296A1 (en) 2013-08-01
CO7101241A2 (es) 2014-10-31
BR112014014786A2 (pt) 2017-06-13
CN104080456A (zh) 2014-10-01
WO2013095166A1 (en) 2013-06-27
PH12014501384A1 (en) 2014-09-22

Similar Documents

Publication Publication Date Title
CL2015001084A1 (es) Compuestos derivados de cefem 2-sustituidos; composicion farmaceutica que los comprende; utiles como agentes efectivos contra bacterias gram negativas que producen beta-lactamasa, incluyendo bacterias resistentes a multiples farmacos, y/o bacterias gram positivas.
CL2014003035A1 (es) Compuestos derivados de diazabiciclooctano, inhibidores de beta-lactamasa; composicion farmaceutica que los comprende; proceso para prepararlos; y metodo para tratar una infeccion bacteriana.
CL2014002589A1 (es) Compuestos inhibidores de beta-lactamasas derivados de 7-oxo-1,6-diazabiciclo[3.2.1] octano; composicion farmaceutica que los comprende y uso para tratar una infeccion bacteriana.
BR112015031475A2 (pt) composto, composição farmacêutica, método para tratamento de uma doença ou condição, kit, e, uso de composto.
SMT201600354B (it) Composti di beta-lattame sostituiti da ammidina, loro preparazione ed uso come agenti antibatterici
CL2016001737A1 (es) Derivados heterocíclicos bicíclicos como inhibidores de bromodominio
BR112015009636A8 (pt) composto, métodos para o tratamento de um hospedeiro infectado, métodos para a prevenção de uma infecção, métodos para a redução da atividade biológica de uma infecção e uso de um composto
BR112014010206A2 (pt) composto, composição farmacêutica, uso de composto, e, método para a profilaxia ou tratamento de um estado ou condição de doença
BR112013030520A2 (pt) método, sistema, e, composição.
WO2012116010A3 (en) Antibiotic tolerance inhibitors
CL2013003129A1 (es) Composicion herbicida de emulsión de aceite en agua, estable de alta resistencia; metodo para preparar dicha composicion.
CL2014002904A1 (es) Una composición geopolimérica de aluminosilicato; metodo de preparacion.
BR112016011830A2 (pt) composições bacterianas sinergísticas e métodos para produção e uso das mesmas.
CL2014000919A1 (es) Compuestos derivados de acido 2-tert-butoxi-2-(5-metilbenzo[d]tiazol-6-il) acetico; composicion farmaceutica que los comprende; metodo para tratar una infeccion por vih; y su uso para tratar una infeccion por vih.
BR112014010179A8 (pt) composto, composição farmacêutica, uso de um composto, e, método para a profilaxia ou tratamento de um estado ou condição
BR112016013509A2 (pt) “sistema para a administração de inoculantes microbianos e materiais e métodos relacionados”.
JP2015528502A5 (es)
LT3251678T (lt) Benzoksaborolo dariniai, skirti bakterinių infekcijų gydymui
BR112015002755A2 (pt) derivado de ácido hialurônico, método de preparação de derivado de ácido hialurônico, método de modificação de derivado de ácido hialurônico e uso de derivados
EP3077633A4 (en) Apparatus and system comprising collapsing and extending mechanisms for actuating engine valves
BR112015008802A2 (pt) combinações de composto ativo, método de controle de fungos, uso de combinações de composto ativo, semente e método para o controle seletivo de plantas.
CL2014002348A1 (es) Compuestos derivados de fenicol; composicion farmaceutica que los comprende; y su uso para controlar o tratar infecciones bacterianas en ganado.
BR112015003259A2 (pt) composto, composição farmacêutica, e, composição de vacina.
WO2012097185A3 (en) Omv vaccine against burkholderia infections
EP3034082A4 (en) Pharmaceutical composition for treating or preventing neuropsychitric disease, containing flavone-6-c-glucose derivatives as active ingredients